Trian Blasts Solventum Board, Citing Lost Value & Executive Pay

NEW YORK, NY – April 30, 2026 – Activist investor Trian Fund Management today launched a blistering public attack on the board of Solventum Corporation (NYSE: SOLV), accusing the 3M spin-off of gross mismanagement, prioritizing executive pay over shareholder returns, and destroying billions in value since its inception. In an open letter and an accompanying presentation, Trian, which holds a nearly 5% stake in the healthcare company, laid out a detailed case for immediate and substantial change.

The move escalates a simmering conflict into a full-blown activist campaign, placing Solventum’s leadership squarely in the crosshairs. Trian, one of Solventum's largest active shareholders, argued that its attempts at constructive, private engagement have been rebuffed, forcing it to take its concerns public. The firm claims it is not alone, stating it has heard from several other large shareholders in recent weeks who share its frustration with the company's trajectory.

A Spin-Off Under Scrutiny

At the heart of Trian's argument is the assertion that Solventum's performance since its separation from former parent 3M has been a profound disappointment. The spin-off, which was intended to unlock value by creating a focused, independent healthcare leader, has instead overseen a massive erosion of shareholder wealth, according to the activist firm.

Trian alleges that the company has suffered a $13 billion loss in shareholder value when measured against the initial $25 billion market capitalization that analysts had projected at the time of the spin. Prior to the separation, some analyst estimates had placed the potential valuation as high as $33 billion. Today, Solventum's market capitalization languishes at just $12 billion.

The irony, as Trian highlights, is that the businesses comprising Solventum were historically the crown jewels of 3M. For years, the Health Care division consistently delivered as 3M's fastest-growing and highest-margin segment, boasting organic growth between 3% and 4% and impressive EBIT margins in the 26% to 27% range. Trian contends that as a standalone entity, Solventum is now significantly underperforming these historical benchmarks, a failure it lays at the feet of the company's current board and management.

The $80 Million Question

Adding fuel to the fire is Trian’s explosive claim regarding executive compensation. The firm's letter singles out the more than $80 million paid to Solventum’s CEO in just over two years. Trian juxtaposes this figure against the company's stagnant stock performance and its modest $12 billion market cap, arguing it represents a staggering disconnect between executive reward and shareholder experience.

This accusation strikes at a contentious issue in modern corporate governance: the alignment of leadership incentives with company performance. For Trian and its supporters, the compensation figures are emblematic of a board that has failed in its primary duty to represent the interests of its owners. The activist investor argues that the spin-off was structured in a way that “maximized executive compensation, not shareholder value,” through what it calls “one of the biggest performance resets of any U.S. spin-off in the last decade.”

The focus on executive pay provides a powerful narrative that resonates beyond institutional investors, raising broader questions about corporate ethics and accountability. While Solventum has yet to issue a direct response to the specific allegations, the figures presented by Trian are certain to draw intense scrutiny from investors, proxy advisory firms, and the wider market.

Trian's Three-Point Turnaround Plan

Beyond its sharp critique, Trian has proposed a clear, three-pronged strategy designed to reverse the company's fortunes and create substantial value. The firm projects that if its plan is implemented, Solventum’s shares could reach $140 by the end of 2027, a significant increase from its current trading levels.

The first initiative calls for right-sizing overhead costs. Trian believes there is a significant opportunity to drive net productivity, strip out unnecessary expenses that have lingered since the spin-off, and reinvest those savings into high-growth areas. The goal is to restore profitability to the levels Solventum consistently achieved while inside 3M.

Second, Trian demands a simplification of Solventum’s portfolio, starting with the immediate separation of its Health Information Systems (HIS) business. This follows the company's recent $4.1 billion sale of its Purification and Filtration unit to Thermo Fisher Scientific, a move Trian had previously described as an “important first step” but not a final one. Divesting the HIS business, Trian argues, would further focus the company on its core, higher-margin medical technology operations.

Finally, the activist is pushing for improved capital allocation, specifically by prioritizing share repurchases at current valuation levels. This is a classic activist playbook maneuver, signaling a strong belief that the company’s stock is fundamentally undervalued and that returning capital to shareholders is the most accretive use of cash.

Wall Street Watches as Pressure Mounts

The public campaign puts Solventum's board in a difficult position. The company's stock currently holds a consensus “Hold” rating from analysts, with an average price target of $89.45, suggesting that Wall Street sees potential upside but remains cautious. Solventum's price-to-earnings (P/E) ratio of approximately 7.6 is significantly below the broader market average, lending some credence to Trian's argument that the company is undervalued relative to its potential.

So far, Solventum's public response has been muted. In a previous statement following Trian's push for more divestitures, a spokesperson noted, “We are excited about the rapid progress we are making to transform Solventum and look forward to continuing to drive value for shareholders.” This boilerplate language will likely no longer suffice in the face of such a direct and detailed public challenge.

The stage is now set for a potential proxy battle if the board does not engage with Trian's proposals or offer a compelling alternative strategy. All eyes are now on Solventum's leadership and its upcoming first-quarter earnings call on May 5, which will be the company's first major opportunity to formally address the activist's pointed critique.